Table 6.
Long-term survival analysis of mRNA expression of TP53, CDKN1A, NME1 and VEGFA in 212 cases of HBV-related HCC in GEO database 14520 data set
| Gene expression | Patients(n=212) | MST (months) | Crude HR (95% CI) | Crude P | Adjusted HR (95% CI) | Adjusted Pa |
|---|---|---|---|---|---|---|
| TP53 | ||||||
| Low | 106 | NA | 1 | 1 | ||
| High | 106 | NA | 1.352(0.874-2.093) | 0.175 | 1.081(0.686-1.703) | 0.737 |
| CDKN1A | ||||||
| Low | 106 | NA | 1 | 1 | ||
| High | 106 | NA | 1.002(0.650-1.545) | 0.993 | 1.058(0.674-1.662) | 0.806 |
| NME1 | ||||||
| Low | 106 | NA | 1 | 1 | ||
| High | 106 | NA | 1.389(0.898-2.149) | 0.140 | 1.316(0.842-2.057) | 0.229 |
| VEGFA | ||||||
| Low | 106 | NA | 1 | 1 | ||
| High | 106 | 54 | 1.735(1.115-2.699) | 0.015 | 1.651(1.035-2.634) | 0.035 |
Notes: a Adjusted for AFP, BCLC stages, number of tumors, tumor size and cirrhosis. p53 also known as tumor protein p53 (TP53), p21 also known as cyclin dependent kinase inhibitor 1A (CDKN1A), nm23also known as nucleoside diphosphate kinase 1 (NME1) and VEGF also known as vascular endothelial growth factor A (VEGFA). HBV, hepatitis B virus; HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein; MST, median survival time; OS, overall survival; HR, hazard ratio; CI, confidence interval; NA, not available.